PT2970980T - Métodos de produção para controlor o teor de lisina c-terminal, galactose e ácido siálico em proteínas recombinantes - Google Patents

Métodos de produção para controlor o teor de lisina c-terminal, galactose e ácido siálico em proteínas recombinantes

Info

Publication number: PT2970980T
Authority: PT; Portugal
Prior art keywords: galactose; control; acid content; sialic acid; manufacturing methods
Prior art date: 2013-03-15

Application number

PT14768761T

Other languages

English (en)

Inventor

Flikweert Marcel

Goochee Charles

Maslanka Francis

Johannes Ignatius Nagel Francisus

Ryland James

Schafer Eugene

Original Assignee

Janssen Biotech Inc

Janssen Biologics B V

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-15

Filing date

2014-03-07

Publication date

2018-11-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51528780&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2970980(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-03-07 Application filed by Janssen Biotech Inc, Janssen Biologics B V filed Critical Janssen Biotech Inc

2018-11-19 Publication of PT2970980T publication Critical patent/PT2970980T/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Life Sciences & Earth Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Microbiology (AREA)

PT14768761T 2013-03-15 2014-03-07 Métodos de produção para controlor o teor de lisina c-terminal, galactose e ácido siálico em proteínas recombinantes PT2970980T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201361791094P	2013-03-15	2013-03-15

Publications (1)

Publication Number	Publication Date
PT2970980T true PT2970980T (pt)	2018-11-19

Family

ID=51528780

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT14768761T PT2970980T (pt)	2013-03-15	2014-03-07	Métodos de produção para controlor o teor de lisina c-terminal, galactose e ácido siálico em proteínas recombinantes

Country Status (27)

Country	Link
US (3)	US20140273092A1 (pt)
EP (1)	EP2970980B2 (pt)
JP (1)	JP2016512029A (pt)
KR (1)	KR102216003B1 (pt)
CN (1)	CN105378086B (pt)
AR (2)	AR095660A1 (pt)
AU (2)	AU2014237635B2 (pt)
BR (1)	BR112015022971B1 (pt)
CA (1)	CA2907140A1 (pt)
CY (1)	CY1120980T1 (pt)
DK (1)	DK2970980T3 (pt)
EA (1)	EA201591807A1 (pt)
ES (1)	ES2690047T3 (pt)
HR (1)	HRP20181741T1 (pt)
IL (1)	IL240689B (pt)
LT (1)	LT2970980T (pt)
MX (1)	MX366910B (pt)
PH (1)	PH12015501837B1 (pt)
PL (1)	PL2970980T3 (pt)
PT (1)	PT2970980T (pt)
RS (1)	RS57791B1 (pt)
SG (1)	SG11201507577RA (pt)
SI (1)	SI2970980T1 (pt)
SM (1)	SMT201800550T1 (pt)
TW (1)	TWI630216B (pt)
WO (1)	WO2014149935A1 (pt)
ZA (1)	ZA201507671B (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9062106B2 (en)	2011-04-27	2015-06-23	Abbvie Inc.	Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en)	2013-03-14	2015-06-30	Abbvie, Inc.	Protein purification using displacement chromatography
US9150645B2 (en)	2012-04-20	2015-10-06	Abbvie, Inc.	Cell culture methods to reduce acidic species
US9181572B2 (en)	2012-04-20	2015-11-10	Abbvie, Inc.	Methods to modulate lysine variant distribution
US9512214B2 (en)	2012-09-02	2016-12-06	Abbvie, Inc.	Methods to control protein heterogeneity
HK1207960A1 (en)	2013-03-12	2016-02-19	Abbvie Inc.	Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en)	2013-03-14	2014-09-25	Abbvie Inc.	Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en)	2013-10-18	2015-04-28	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same using displacement chromatography
KR102216003B1 (ko) *	2013-03-15	2021-02-16	얀센 바이오테크 인코포레이티드	재조합 단백질에서 c-말단 라이신, 갈락토스 및 시알산 함량을 제어하기 위한 제조 방법
US10196601B2 (en)	2013-08-20	2019-02-05	Lek Pharmaceuticals D.D.	Cell culture medium and process for controlling α-amidation and/or C-terminal amino acid cleavage of polypeptides
US9598667B2 (en)	2013-10-04	2017-03-21	Abbvie Inc.	Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en)	2013-10-18	2015-07-21	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same
US9181337B2 (en)	2013-10-18	2015-11-10	Abbvie, Inc.	Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en)	2013-11-15	2015-05-21	Abbvie, Inc.	Glycoengineered binding protein compositions
MY198562A (en)	2015-11-03	2023-09-05	Janssen Biotech Inc	Antibodies specifically binding pd-1 and their uses
WO2017083224A1 (en) *	2015-11-09	2017-05-18	Bristol-Myers Squibb Company	Methods to manipulate quality attributes of polypeptides produced in cho cells
BR112018012344A2 (pt)	2015-12-17	2018-12-04	Janssen Biotech Inc	anticorpos que se ligam especificamente a hla-dr e seus usos
EP4310503A3 (en)	2015-12-30	2024-03-20	Momenta Pharmaceuticals, Inc.	Methods related to biologics
CA3033665A1 (en)	2016-08-12	2018-02-15	Janssen Biotech, Inc.	Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
SG11201900746RA (en)	2016-08-12	2019-02-27	Janssen Biotech Inc	Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
EP4467565A3 (en)	2016-12-21	2025-03-12	Amgen Inc.	Anti-tnf alpha antibody formulations
KR102692379B1 (ko)	2017-06-05	2024-08-05	얀센 바이오테크 인코포레이티드	Pd-1과 특이적으로 결합하는 항체 및 사용 방법
AU2018281045A1 (en)	2017-06-05	2019-12-12	Janssen Biotech, Inc.	Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations
WO2019077628A1 (en) *	2017-10-16	2019-04-25	Council Of Scientific & Industrial Research	ZINC SUPPLEMENTATION TO DECREASE GALACTOSYLATION OF RECOMBINANT GLYCOPROTEINS
US12398209B2 (en)	2018-01-22	2025-08-26	Janssen Biotech, Inc.	Methods of treating cancers with antagonistic anti-PD-1 antibodies
JP2021524255A (ja)	2018-05-24	2021-09-13	ヤンセンバイオテツク，インコーポレーテツド	単一特異性及び二重特異性抗体抗−ｔｍｅｆｆ２抗体並びにそれらの使用
TWI874341B (zh)	2018-12-18	2025-03-01	美商健生生物科技公司	產生異二聚體抗體之方法
BR112021012973A2 (pt) *	2018-12-31	2021-09-14	Momenta Pharmaceuticals, Inc.	Métodos de produção de ustequinumabe
CA3147735A1 (en)	2019-07-26	2021-02-04	Janssen Biotech, Inc.	Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
CA3148121A1 (en)	2019-08-15	2021-02-18	Janssen Biotech, Inc.	Materials and methods for improved single chain variable fragments
PE20240020A1 (es)	2020-03-13	2024-01-04	Janssen Biotech Inc	Materiales y metodos para la union de siglec-3/cd33
JP2023528350A (ja)	2020-05-27	2023-07-04	ヤンセンバイオテツク，インコーポレーテツド	Ｃｄ３抗原結合ドメインを含むタンパク質及びその使用
AU2021317111A1 (en)	2020-07-29	2023-03-30	Janssen Biotech, Inc.	Proteins comprising HLA-G antigen binding domains and their uses
CA3198590A1 (en)	2020-10-13	2022-04-21	Rajkumar Ganesan	Bioengineered t cell mediated immunity, materials and other methods for modulating cluster of differentiation iv &/or viii
TW202233672A (zh)	2020-10-22	2022-09-01	美商健生生物科技公司	包括類δ配體３（ＤＬＬ３）抗原結合區之蛋白質及其用途
PE20240761A1 (es)	2021-01-28	2024-04-17	Janssen Biotech Inc	Proteinas de union a psma y usos de estas
KR20230160353A (ko)	2021-03-24	2023-11-23	얀센 바이오테크 인코포레이티드	Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도
TW202304986A (zh)	2021-03-24	2023-02-01	美商健生生物科技公司	靶向cd22及cd79b的抗體
JP2024533457A (ja)	2021-09-13	2024-09-12	ヤンセンバイオテツク，インコーポレーテツド	がんの治療のためのＣＤ３３×Ｖδ２多重特異性抗体
WO2023046322A1 (en)	2021-09-24	2023-03-30	Janssen Pharmaceutica Nv	Proteins comprising cd20 binding domains, and uses thereof
WO2023089587A1 (en)	2021-11-22	2023-05-25	Janssen Biotech, Inc.	Compositions comprising enhanced multispecific binding agents for an immune response
WO2024089551A1 (en)	2022-10-25	2024-05-02	Janssen Biotech, Inc.	Msln and cd3 binding agents and methods of use thereof
US20250136688A1 (en)	2023-08-07	2025-05-01	Janssen Biotech, Inc.	Stabilized cd3 antigen binding agents and methods of use thereof
WO2025032508A1 (en)	2023-08-07	2025-02-13	Janssen Biotech, Inc.	Enpp3 and cd3 binding agents and methods of use thereof
WO2025137410A1 (en) *	2023-12-20	2025-06-26	Apogee Therapeutics, Inc.	Pharmaceutical compositions of anti-il-13 antibodies with and without c-terminal lysine

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4376110A (en)	1980-08-04	1983-03-08	Hybritech, Incorporated	Immunometric assays using monoclonal antibodies
US4870163A (en)	1985-08-29	1989-09-26	New York Blood Center, Inc.	Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
DE3631229A1 (de)	1986-09-13	1988-03-24	Basf Ag	Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
US5075236A (en)	1987-04-24	1991-12-24	Teijin Limited	Method of detecting kawasaki disease using anti-tumor necrosis antibody
DE69027121T3 (de)	1989-08-07	2001-08-30	Peptech Ltd., Dee Why	Bindeligande für tumornekrosisfaktor
US6277969B1 (en) *	1991-03-18	2001-08-21	New York University	Anti-TNF antibodies and peptides of human tumor necrosis factor
EP1681305A3 (en)	1991-03-18	2008-02-27	New York University	Monoclonal and chimeric antibodies specific for human tumor necrosis factor
US7192584B2 (en)	1991-03-18	2007-03-20	Centocor, Inc.	Methods of treating psoriasis with anti-TNF antibodies
US5919452A (en)	1991-03-18	1999-07-06	New York University	Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
FR2807767B1 (fr) †	2000-04-12	2005-01-14	Lab Francais Du Fractionnement	Anticorps monoclonaux anti-d
UA81743C2 (uk)	2000-08-07	2008-02-11	Центокор, Инк.	МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
CA2450289A1 (en) †	2003-03-20	2005-05-19	Imclone Systems Incorporated	Method of producing an antibody to epidermal growth factor receptor
US20040185047A1 (en)	2003-03-21	2004-09-23	Jill Giles-Komar	Anti- TNF antibodies, compositions, methods and uses
DE602005026548D1 (de) †	2004-11-02	2011-04-07	Ares Trading Sa	Serumfreies kulturmedium für säugerzellen
ES2517603T3 (es) *	2008-04-07	2014-11-03	Bayer Healthcare, Llc	Procedimientos de producción recombinante de glucoproteínas
RU2580020C2 (ru) *	2011-04-29	2016-04-10	Биокон Рисерч Лимитед	Способ снижения гетерогенности антител и способ получения соответствующих антител
CN103717729B (zh)	2011-07-08	2017-11-21	动量制药公司	细胞培养方法
US9181572B2 (en)	2012-04-20	2015-11-10	Abbvie, Inc.	Methods to modulate lysine variant distribution
KR102216003B1 (ko) *	2013-03-15	2021-02-16	얀센 바이오테크 인코포레이티드	재조합 단백질에서 c-말단 라이신, 갈락토스 및 시알산 함량을 제어하기 위한 제조 방법

2014
- 2014-03-07 KR KR1020157029490A patent/KR102216003B1/ko not_active Expired - Fee Related
- 2014-03-07 AU AU2014237635A patent/AU2014237635B2/en not_active Ceased
- 2014-03-07 JP JP2016500790A patent/JP2016512029A/ja active Pending
- 2014-03-07 CN CN201480015815.5A patent/CN105378086B/zh not_active Expired - Fee Related
- 2014-03-07 RS RS20181228A patent/RS57791B1/sr unknown
- 2014-03-07 EP EP14768761.0A patent/EP2970980B2/en active Active
- 2014-03-07 SI SI201430848T patent/SI2970980T1/sl unknown
- 2014-03-07 ES ES14768761.0T patent/ES2690047T3/es active Active
- 2014-03-07 WO PCT/US2014/021574 patent/WO2014149935A1/en not_active Ceased
- 2014-03-07 SG SG11201507577RA patent/SG11201507577RA/en unknown
- 2014-03-07 CA CA2907140A patent/CA2907140A1/en active Pending
- 2014-03-07 HR HRP20181741TT patent/HRP20181741T1/hr unknown
- 2014-03-07 LT LTEP14768761.0T patent/LT2970980T/lt unknown
- 2014-03-07 PL PL14768761T patent/PL2970980T3/pl unknown
- 2014-03-07 MX MX2015012361A patent/MX366910B/es active IP Right Grant
- 2014-03-07 BR BR112015022971-9A patent/BR112015022971B1/pt not_active IP Right Cessation
- 2014-03-07 DK DK14768761.0T patent/DK2970980T3/en active
- 2014-03-07 EA EA201591807A patent/EA201591807A1/ru unknown
- 2014-03-07 PT PT14768761T patent/PT2970980T/pt unknown
- 2014-03-07 SM SM20180550T patent/SMT201800550T1/it unknown
- 2014-03-13 TW TW103108900A patent/TWI630216B/zh not_active IP Right Cessation
- 2014-03-13 US US14/207,915 patent/US20140273092A1/en not_active Abandoned
- 2014-03-13 AR ARP140100976A patent/AR095660A1/es not_active Application Discontinuation
2015
- 2015-08-20 IL IL240689A patent/IL240689B/en unknown
- 2015-08-20 PH PH12015501837A patent/PH12015501837B1/en unknown
- 2015-10-14 ZA ZA2015/07671A patent/ZA201507671B/en unknown
- 2015-12-23 US US14/757,691 patent/US11149085B2/en not_active Expired - Fee Related
2018
- 2018-11-02 CY CY181101150T patent/CY1120980T1/el unknown
2020
- 2020-06-11 AU AU2020203864A patent/AU2020203864B2/en not_active Ceased
2021
- 2021-09-29 US US17/489,744 patent/US20220089712A1/en not_active Abandoned
2022
- 2022-02-14 AR ARP220100291A patent/AR124871A2/es unknown

Also Published As

Publication number	Publication date
WO2014149935A1 (en)	2014-09-25
BR112015022971A2 (pt)	2017-11-14
CY1120980T1 (el)	2019-12-11
TW201441263A (zh)	2014-11-01
RS57791B1 (sr)	2018-12-31
LT2970980T (lt)	2018-10-25
EA201591807A1 (ru)	2016-02-29
SI2970980T1 (sl)	2018-11-30
AU2020203864B2 (en)	2022-05-26
ZA201507671B (en)	2017-11-29
KR20150129025A (ko)	2015-11-18
HRP20181741T1 (hr)	2018-12-28
CA2907140A1 (en)	2014-09-25
ES2690047T3 (es)	2018-11-19
US20140273092A1 (en)	2014-09-18
PH12015501837B1 (en)	2022-02-11
US20220089712A1 (en)	2022-03-24
SMT201800550T1 (it)	2019-01-11
TWI630216B (zh)	2018-07-21
BR112015022971B1 (pt)	2022-05-17
EP2970980B1 (en)	2018-08-15
PH12015501837A1 (en)	2015-11-09
MX366910B (es)	2019-07-30
AU2014237635A1 (en)	2015-09-03
CN105378086B (zh)	2019-05-28
EP2970980A4 (en)	2016-09-07
AU2020203864A1 (en)	2020-07-02
SG11201507577RA (en)	2015-10-29
US11149085B2 (en)	2021-10-19
EP2970980B2 (en)	2022-07-27
MX2015012361A (es)	2016-04-28
PL2970980T3 (pl)	2019-01-31
CN105378086A (zh)	2016-03-02
EP2970980A1 (en)	2016-01-20
DK2970980T3 (en)	2018-10-22
JP2016512029A (ja)	2016-04-25
IL240689B (en)	2021-12-01
KR102216003B1 (ko)	2021-02-16
AR095660A1 (es)	2015-11-04
IL240689A0 (en)	2015-10-29
US20160237149A1 (en)	2016-08-18
AR124871A2 (es)	2023-05-17
AU2014237635B2 (en)	2020-03-12

Publication	Publication Date	Title
ZA201507671B (en)	2017-11-29	Manufacturing methods to control c-terminal lysine, galactose and sialic acid content in recombinant proteins
WO2014151878A3 (en)	2015-01-22	Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
IL243902A0 (en)	2016-04-21	An antibody that specifically binds to glp-1r and its fusion protein with glp-1
ZA201503097B (en)	2018-11-28	Production of recombinant vaccine in e. coli by enzymatic conjugation
IL279676A (en)	2021-03-01	Recombinant proteins and therapeutic uses
IL232073A0 (en)	2014-05-28	Recombinant human naglu protein and its uses
CL2014003568A1 (es)	2015-04-24	Células transformadas para producir iduronato-2-sulfatasa (i2s) recombinante; método de producción de i2s recombinante; y proteína i2s recombinante.
SG11201505195TA (en)	2015-08-28	Methods For Reducing Aggregate Content In Protein Preparations
EP2947143A4 (en)	2016-07-06	RECOMBINANT CELL, AND PROCESS FOR PRODUCING 1,4-BUTANEDIOL
EP3083966A4 (en)	2017-11-15	Method for in vivo production of deglycosylated recombinant proteins used as substrate for downstream protein glycoremodeling
IN2014DN00161A (pt)	2015-05-22
SG11201403814RA (en)	2014-10-30	Production of recombinant proteins with simple glycoforms
EP2971035A4 (en)	2016-11-09	RECOMBINED POLYPEPTIDE PRODUCTION
BR112014025693A2 (pt)	2018-08-07	método de produção recombinante de polipeptídeos em células procarióticas
EP3000890A4 (en)	2017-02-01	Alphaviral vectors and cell lines for producing recombinant proteins
GB201306114D0 (en)	2013-05-22	Improvements in and relating to the production and control of ions
GB201304973D0 (en)	2013-05-01	Recombinant protein
SG11201600682PA (en)	2016-02-26	Expression vector for production of recombinant proteins in prokaryotic host cells
SG11201404180RA (en)	2014-08-28	Cho-gmt recombinant protein expression
IL240639A0 (en)	2015-09-24	Formulations and methods for increased recombinant production of protein
GB201308120D0 (en)	2013-06-12	Recombinant protein and method for its production
SG11201600725WA (en)	2016-02-26	Method for the recombinant production of a polypeptide in prokaryotic cells
EP3025725A4 (en)	2016-12-21	PREPARATION FOR SUBCUTANEOUS INJECTION TO INDUCE BOVINE SUPEROVULATION
GB201320209D0 (en)	2014-01-01	Improvements in or relating to protein Micro-nets
GB201315578D0 (en)	2013-10-16	Protein delivery to membranes